Bug-Resistant Medicines Sales Forecasts Reveal Positive Growth Through 2028

Author: Apurva Deshpande

Bug-resistant medicines are the drugs which are used to stop the infection that is caused by the germs or the bugs i.e. antimicrobials in many cases. There are several drugs which are approved by food and drug administration recently like Ceftolozane/tazobactam, Sivextro, Zerbaxa among others that fight against these kinds of bugs (bacterial strains). When bugs resist several varieties of the antibiotics, then they are known as superbugs. According to the Centers for Disease Control and Prevention (CDC), Antibiotic-Resistant Superbug is becoming an emerging threat to all the people across the world. Thus, Bug-resistant medicines are introduced in this way to the Bug-resistant medicines market. Increase in such kind of infection increases the demand of the bug resistant disease. Around 70% of the bugs that cause such kind of infections are resistant to at least one of the antibiotics generally needed to treat them. 490 000 people developed multi-drug resistant Tuberculosis across the world, and drug resistance is outset to impede the fight against deadly diseases such as HIV and malaria in 2016.

As per the Centers for Disease Control and Prevention (CDC), drug-resistant infections reported for around 2 million infections with antimicrobial-resistant bacteria that leads to approximately 23,000 deaths in the United States of America annually. Increasing the prevalence of chronic diseases across the globe drives the Bug-resistant medicines market. Manufacturers are focusing on the research and development of such type of drugs which helps the patient to recover at the earliest. These bugs can spread mostly from patients in hospitals. Some of the applications that bug-resistant medicines offers include oncology, immunology, neurology, cardiology, respiratory, infectious diseases and others. Other factors such as the increased burden of genetic diseases such as diabetes among others are expected to boost the growth of the bug-resistant medicines market. The mutation occurs in the microbial strains causes its behavior negative to these medicines.

Request Sample Report@ https://www.persistencemarketresearch.com/samples/26179

Generally, the global Bug-Resistant Medicines market can be segmented on the basis of Drugs, distribution channel & regions.

On the basis of Drugs, the Bug-Resistant Medicines market is segmented as:

  • Antiviral
  • Antifungal
  • Antibacterial
  • Others

On the basis of distribution channel, the Bug-Resistant Medicines market is segmented as:

  • Hospitals
  • Clinics
  • Ambulatory Care Center
  • Others

The global Bug-Resistant Medicines market is expected to grow with a moderately increasing CAGR due to the increasing adoption and demand for Bug-Resistant Medicines. Based on the Drugs, it is observed that Antibacterial is done at most of the cases. It is analyzed that, On the basis of end users, hospital segment will hold the maximum market revenue share in the global Bug-Resistant Medicines market over the forecast period. One of the most common uses of Bug-Resistant Medicines is to control the effect of bugs i.e. infection

Request Report TOC@ https://www.persistencemarketresearch.com/methodology/26179

On the basis of geography, the global Bug-Resistant Medicines market is segmented into six key regions viz. North America, Latin America, Europe, the Asia Pacific excluding China, China, and the Middle East & Africa. The North America Bug-Resistant Medicines market is expected to contribute maximum market share in the global Bug-Resistant Medicines market which is followed by Europe Bug-Resistant Medicines market. The Asia Pacific Bug-Resistant Medicines market is expected to grow with a maximum CAGR over the forecast period due to less awareness among the people while the Latin America Bug-Resistant Medicines market and the Middle East and Africa concerned market is expected to show steady growth rate over the forecast period. It is estimated that the Middle East and Africa concerned market is to be dominated by South Africa.

Some of the key players present in the global concerned market are F. Hoffmann-La Roche Ltd, Sanofi, Novartis International AG, Pfizer Inc. AbbVie Inc. Gilead, Amgen Inc., GlaxoSmithKline plc. Johnson & Johnson Services, Inc. among others.